Evidence map›Paper›PMID 41907096›Full record

ArticleCellular and molecular bioengineering2026

Melanoma/CSPG4-Enhanced Collagen-Mediated Contact Guidance Requires Mutant Active BRAF and the CSPG4 Core Protein Cytoplasmic Domain.

G Thrivikraman, J Yang, M Price, A Giubellino, J B McCarthy, R T Tranquillo

Abstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

G ThrivikramanDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455 USA.
J YangDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 USA.
M PriceDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 USA.
A GiubellinoDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 USA.
J B McCarthyDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 USA.
R T TranquilloDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chondroitin sulfate proteoglycan-4 (CSPG4) is a transmembrane cell surface proteoglycan that promotes malignant progression in melanoma. Elevated CSPG4 expression in melanoma cells is associated with several malignant phenotypic properties, including increased tumor cell invasion, tumorigenic potential, and metastasis. Methods: Magnetically aligned collagen gels with entrapped cells were used to model the aligned extracellular matrix in the tumor microenvironment and to identify the key role of CSPG4 in sensing contact guidance. Results: The data show that CSPG4-expressing WM1552C Radial Growth Phase (RGP) melanoma cells exhibit enhanced contact guidance along with increased migration speed in contrast to paired counterparts that lack CSPG4. This required the presence of a pERK 1,2 phospho-acceptor site on the cytoplasmic tail of the core protein. Furthermore, short-term treatment of CSPG4-expressing cells with the clinically used mutant active BRAF inhibitor vemurafenib reduced both guidance and speed. Conclusions: These findings support the role of CSPG4 overexpression and mutant active BRAF-in promoting increased contact guidance. The results are discussed in terms of expanding what is known about the potential tumor biology and clinical implications of CSPG4-related impact on malignant invasion during early phases of melanoma progression. Supplementary Information: The online version contains supplementary material available at 10.1007/s12195-025-00882-x.

Indexed as

Aligned collagenChondroitin sulfate proteoglycan-4Contact guidanceMelanoma

Identifiers

PMID41907096
PMCPMC13031561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.